Go
Contact Us
Small
Medium
Large
Text Size
Home
Company
Management
Board of Directors
Corporate Governance
Collaborators
Technology Licenses
Ethics and Compliance
History
Social Responsibility
Locations
Contact
Products
ARCALYST
®
(rilonacept)
EYLEA™ (aflibercept) Injection
Pipeline
Inflammation
Metabolism
Oncology
Ophthalmology
Pain
Science
Scientific Leadership
Therapeutic Focus Areas
Target Discovery
Drug Candidate Platforms
Protein Production
Publications
Investors
Media
Press Releases
Events and Presentations
Financial Information
Stock Information
Corporate Governance
Investor FAQs
Investor Contact
Careers
Working at Regeneron
Our Organization
Benefits
Search Jobs
Investors
Dividend History
Email
Print
Investors
Media
Press Releases
Contact Media Relations
E-Press Kit
Image Gallery
Press Releases
Events and Presentations
SEC Filings
Financial Information
Annual Reports and Proxy Statements
Quarterly Reports
Key Ratios
Stock Information
Historic Stock Lookup
Investment Calendar
Analyst Coverage
Analyst Estimates
Ownership Profile
Corporate Governance
Committee Composition
Contact the Board
Insider Transactions
Investor FAQs
Investor Contact
Featured Report
2010
Annual Report and 10K
2011
Proxy Statement
Shareholder Tools
Shareholder Briefcase
E-mail Alerts
Download Library
REGN Snapshot
RSS News Feeds
The Company has never paid a dividend.
Close Video
Close Window
Form content here please :)
Shareholder Briefcase
E-mail Alerts
Download Library
REGN Snapshot
RSS News Feeds